Osteopathic Manipulative Treatment (OMT) for Covid19

Phase-Based Progress Estimates
Covid19+6 More
Osteopathic Manipulative Treatment (OMT) - Other
All Sexes
What conditions do you have?

Study Summary

This trial will test if adding osteopathic manipulative treatment to current mRNA COVID-19 vaccines can enhance the immune response.

Eligible Conditions
  • Covid19

Treatment Effectiveness

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: Through study completion, an average of 1 year

Year 1
IgG antibody titer levels Percentage Change
IgM antibody titer levels Percentage Change.
Year 1
IgM and IgG antibody titer duration
Year 1
Adverse Effects/Side Effects
Medication Usage

Trial Safety

Trial Design

2 Treatment Groups

1 of 2
OMT Intervention Arm
1 of 2
Active Control
Experimental Treatment

200 Total Participants · 2 Treatment Groups

Primary Treatment: Osteopathic Manipulative Treatment (OMT) · No Placebo Group · N/A

OMT Intervention Arm
Experimental Group · 1 Intervention: Osteopathic Manipulative Treatment (OMT) · Intervention Types: Other
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

American College of Osteopathic PhysiciansUNKNOWN
Xavier-Nichols FoundationUNKNOWN
Western University of Health SciencesLead Sponsor
19 Previous Clinical Trials
1,057 Total Patients Enrolled
American Osteopathic FoundationUNKNOWN
1 Previous Clinical Trials
20 Total Patients Enrolled
Osteopathic Physicians and Surgeons of CaliforniaUNKNOWN
Jesus Sanchez, DO4.04 ReviewsPrincipal Investigator - Professor of Family Medicine
Western University of Health Sciences

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
I will be receiving the mRNA COVID-19 vaccine at Western University of Health Sciences.
Are 18 to 65 years old.
I have not previously received a COVID-19 vaccine.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: October 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.